This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Statistics and Research Methods  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Drug Therapy  • Drug Therapy, Other  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Debabrata Mukherjee, MD; David J. Moliterno, MD

JAMA. 2008;299(4):454-455.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drug-eluting stents are a major advance in percutaneous coronary intervention (PCI) because they reduce the need for repeat target lesion revascularization several-fold compared with bare-metal stents. Early randomized clinical trials separately testing sirolimus-eluting stents^1-2 and paclitaxel-eluting stents^3-4 against their bare-metal counterparts demonstrated that rates of target lesion revascularization were reduced from approximately 10% to 15% to approximately 4% to 5%, whereas the rates of death, myocardial infarction, and stent thrombosis were similar between bare-metal and drug-eluting stents. Because these studies were performed for device regulatory approval, they enrolled patients and lesions with relatively low risk for restenosis and adverse events. Subsequent head-to-head trials of sirolimus- and paclitaxel-eluting stents in cohorts with a broader risk profile have provided inconsistent results; some trials have suggested equivalent rates of target lesion revascularization for these stents,^5-6 whereas others have reported superiority of sirolimus-eluting stents.^7-9

Initial clinical trials . . . [Full Text of this Article]

Author Affiliations: Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
Anders M. Galløe, Leif Thuesen, Henning Kelbæk, Per Thayssen, Klaus Rasmussen, Peter R. Hansen, Niels Bligaard, Kari Saunamäki, Anders Junker, Jens Aarøe, Ulrik Abildgaard, Jan Ravkilde, Thomas Engstrøm, Jan S. Jensen, Henning R. Andersen, Hans E. Bøtker, Søren Galatius, Steen D. Kristensen, Jan K. Madsen, Lars R. Krusell, Steen Z. Abildstrøm, Ghita B. Stephansen, Jens F. Lassen, and for the SORT OUT II Investigators
JAMA. 2008;299(4):409-416.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Minimally Invasive Hybrid Coronary Artery Revascularization
Holzhey et al.
Ann. Thorac. Surg. 2008;86:1856-1860.
ABSTRACT | FULL TEXT  

Outside the operating room--economic, regulatory, and legal challenges: A collection of perspectives and panel discussion
ALTMAN et al.
Cleveland Clinic Journal of Medicine 2008;75:S61-S73.
FULL TEXT  

Progress Is Precarious
Head and Barash
Anesth. Analg. 2008;107:362-364.
FULL TEXT  

Performance of Drug-Eluting Stents in Usual Clinical Practice
JWatch General 2008;2008:6-6.
FULL TEXT  

Are Sirolimus-Eluting and Paclitaxel-Eluting Stents Equivalent?
Journal Watch Cardiology 2008;2008:3-3.
FULL TEXT